Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

19 Sept 2011

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 21933749
DOI: 10.1016/s1470-2045(11)70232-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisPMID 21933749Read ↗

Management of NSCLC: focus on crizotinib.Semantic proximity Read ↗

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.Semantic proximity Read ↗

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.Semantic proximity Read ↗

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinibSemantic proximity Read ↗

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with CrizotinibSemantic proximity Read ↗

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read ↗

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitorsSemantic proximity Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.Semantic proximity Read ↗

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.Semantic proximity Read ↗

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.